Ekso Bionics® to Present and Exhibit at the 6th International Conference of Rehabilitation Medicine and Engineering in Shanghai

RICHMOND, Calif., May 18, 2017 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced that the company will be presenting and exhibiting at the 6th International Conference of Rehabilitation Medicine and Engineering (CRME 2017), being held in Shanghai, China, on May 20 – 21, 2017.

CRME 2017 is an annual meeting organized by Shanghai Jiao Tong University and the National Rehabilitation Aids Research Center to bring together well-known international experts to discuss the rapid development and collaboration between rehabilitative medicine and the digital age.

Ekso Bionics will present an overview of the company and the clinical benefits of the EksoGT™, a wearable exoskeleton device designed to rehabilitate patients with stroke and spinal cord injuries.

The presentation details are as follows:

Presentation Title:    Ekso Bionics and the Benefits of Robotic Rehabilitation
Date:    Saturday, May 20, 2017 
Time:    12:15pm – 1:15pm 
Location:    Dahua Hongqiao Holiday Inn Hotel, Yihua Hall, 2nd Floor 
Presenters:

  Josip Markus, Director, Business Development, Ekso
Bionics
Barry Richards, EMEA Clinical Director, Ekso Bionics

“We are excited to showcase the EksoGT at this international forum and to present the unique rehabilitation benefits the technology provides,” commented Thomas Looby, Ekso Bionics’ President and Chief Executive Officer. “China has the world’s largest stroke and spinal cord injury patient populations, but faces a shortage of licensed rehabilitation specialists.  This, in turn, has created a real need for new technologies, like the EksoGT, to maximize care and improve patient outcomes.”

CRME 2017 attendees are also invited to see a demonstration of the EksoGT and learn more about this innovative technology at the Ekso Bionics booth, #A2. 

For more information about Ekso Bionics or EksoGT, visit www.eksobionics.com.

About EksoGT™
EksoGT™ is the first exoskeleton cleared by the FDA for use with stroke and spinal cord injuries from L5 to C7. The EksoGT with SmartAssist™ software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped patients take more than 70 million steps in over 130 rehabilitation institutions around the world.

About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing to fund the Company’s operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company’s products, the Company’s failure to achieve broad market acceptance of the Company’s products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company’s medical device products, the failure to obtain or maintain patent protection for the Company’s technology, failure to obtain or maintain regulatory approval to market the Company’s medical devices, lack of product diversification, existing or increased competition, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.

CONTACT: Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com

Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com

Logo Header Menu